Loading quotes...

Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

Cocrystal Pharma pivots with new CEO, OPKO investment and norovirus antiviral readout due Q4 2026

Cocrystal Pharma appointed James Sapirstein as CEO, reorganized leadership and strengthened the board with experienced pharma executives to push commercialization. OPKO invested $5.0 million in a common-equity private placement, extending runway to roughly seven months at current burn rates. The company’s lead candidate CDI-988, an oral 3CL protease inhibitor for norovirus, holds FDA Fast Track designation and is in a Phase 1b human challenge study with topline data expected late Q4 2026. Key risks include Phase 1 clinical and regulatory uncertainty and potential dilution despite the shareholder-friendly financing terms. » More on finance.yahoo.com

Financials

In the last quarter, Cocrystal Pharma Inc had revenue of €92k and net profit of -€2.77m

(EUR)	June 2026	YoY
Revenue	92k	-
Gross profit	92k	-
Net profit	-2.77m	59.01%
EBITDA	-2.76m	60.04%

Fundamentals

Metric	Value
Market capitalization	€16.92m
Number of shares	19.26m
52-week high/low	€1.82 - €0.68
Dividends	No
Beta	1.48
P/E ratio	-1.23
PEG ratio	-0.03
P/B ratio	12.95
P/S ratio	57.26

Company profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.